Shareholder and Investor Information | RaQualia Pharma Inc.

Home
Shareholder and Investor Information

2012.02.16
Summary of Business Report for the fourth fiscal year ended December 31, 2011
2012.02.08
Start of Phase II Study of the 2nd Generation (Atypical) Antipsychotic Drug Ziprasidone in Japan
2012.01.31
Composition of Matter Patent for Acid Pump Antagonist Approved in Korea
2011.12.29
Announcement of Execution of Letter of Intent Regarding COX-2 Inhibitor
2011.11.11
Summary of Financial Results for the 3Q ended September 30, 2011
2011.08.01
Executive Appointment
2011.07.28
CJ CheilJedang Co. and RaQualia Sign License Agreement for 5-HT4 Partial Agonist
2011.07.20
RaQualia announces that its common shares were listed on the Osaka Securities Exchange JASDAQ Growth Market today

Corporate Information: CEO Message; Company Overview; Vision, Management Principle and Culture; Corporate Governance; Business Model; Origins of Our Corporate Name and Logo; Facilities; Access; Press Release
Research & Development: Collaboration; Partnering in Research; What are Research Tools?; Research Tool Licensing

Product Information: Anidulafungin; Ziprasidone; Dalbavancin; EP₄ Antagonist; Cyclooxygenase-2 (COX-2) Inhibitor; Ghrelin Receptor Agonist; 5-HT₄ Partial Agonist; Acid Pump Antagonist; 5-HT_2B Antagonist; CB₂ Agonist; Motilin Receptor Agonist; Licensing

Shareholder and Investor Information

To our Shareholders and Investors

Vision, Management Principle and Culture

Corporate Governance

Outline of Securities Matters

IR Related News

Understanding RaQualia Pharma! RaQualia FAQ: RaQualia's History; What does RaQualia Pharma do?; How Does RaQualia Earn Revenues?; What About Dividends?; What are RaQualia's strengths?; What Does the Future Hold for RaQualia Pharma?

Corporate Introduction Video
Contributions to Society: Corporate Contributions; Contributions to the Community; Press Release; Topics